Document is current
Any future updates will be listed below
-
Authors
Fay, Felix
Ruscheweyh, Ruth
Straube, Andreas
Eren, Ozan Emre
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 2 August 2025
Accepted: 30 October 2025
First Online: 6 November 2025
Declarations
:
: The study received approval from the Ethics Committee of Ludwig Maximilians University Munich (22–0647). All included participants have signed a general consent form agreeing to the anonymized analysis and publication of the produced measures.
: FF: no potential conflicts of interest. RR: Speaker and/or consultant, as well as covered travel fees by Allergan, Lilly, Lundbeck, Pfizer, Novartis and Teva. AS: Speaker and/or consultant for Allergan, Novartis, Lundbeck, Lilly, Sanofi and TEVA. Financial support for his research by Novartis, Innovation Fund, German Research Association (DFG) and University of Munich (LMU). OE: Speaker and/or consultant for Lilly and Novartis. Financial support for his research by the German Federal Ministry of Education and Research (BMBF), German Migraine and Headache Society (DMKG), Friedrich Baur Institute.
